Vasi Pharma

03/04/2026

Closing the TNBC Treatment Gap

Triple-negative breast cancer (TNBC) is a large, urgent need: of the ~316,950 U.S. women expected to be diagnosed with invasive breast cancer in 2025, about 10–15% - roughly 32,000–48,000 women - will have TNBC. Outcomes remain poorer than other subtypes: five-year relative survival is ~91% when localized, 66% with regional spread, and 12% when metastatic (77% across all stages), and in the metastatic setting median overall survival is only ~11–13 months with ~11% five-year survival. Even with modern chemo-immunotherapy that improves pathologic complete response and event-free survival in early-stage disease, many patients still relapse. 2216 is our investigational small-molecule lead designed to address this gap by selectively modulating a tumor-survival pathway implicated in TNBC proliferation and treatment resistance; we’re optimizing potency, selectivity, and combination-ready pharmacology to support deep, durable target engagement while maintaining an acceptable safety margin, with ongoing preclinical studies focused on antitumor activity and biomarker-guided patient selection. (2216 is investigational and not approved.)

03/04/2026

Our Mission

To revolutionize the drug discovery process by integrating biology, chemistry, and artificial intelligence, delivering novel therapeutics to patients with speed, precision, and purpose.

03/04/2026

Good health tips

03/04/2026

03/04/2026

Now Hiring – Remote Customer Support (Work From Home)

At Vasi Pharma, we are looking for reliable individuals to join our team!

• Work from home
• Full-time & part-time available
• Monday–Saturday (flexible hours)
• $25 per hour
• No experience required (training provided)

Responsibilities include responding to customer emails/chats and assisting with orders and account updates.

Interested? Send a direct message with your name and availability for more details.

01/27/2026

Prostate cancer is one of the most common cancers affecting men, particularly as they age. The prostate is a small gland located below the bladder that plays a role in producing seminal fluid. Prostate cancer occurs when abnormal cells in the prostate grow uncontrollably.

01/13/2026

Artificial Intelligence
AI speeds up discoveries by analyzing data and finding patterns to drive innovation across all fields.

01/10/2026

Alzheimer’s disease remains a vast, urgent problem—about 7.2 million Americans age 65+ are living with Alzheimer’s dementia in 2025, and once diagnosed, people typically survive ~4–8 years (some longer), reflecting a progressive loss of independence and high caregiver burden. Recently approved anti-amyloid antibodies have moved the field forward but leave substantial unmet need: lecanemab slowed clinical decline by 27% on CDR-SB at 18 months in early AD, and donanemab earned FDA approval after a Phase 3 trial showing significantly slowed cognitive and functional decline (reported as ~35% in sponsor disclosures). 60xx is our investigational small-molecule program aimed at complementing these modalities by addressing upstream drivers of neurodegeneration (e.g., synaptic loss and neuroinflammatory pathways). We’re optimizing 60xx for high CNS-relevant potency and drug-like properties with a biomarker-guided strategy to enable rational combinations and patient selection—ultimately aiming to translate into slower decline and longer, higher-quality survival than today’s options. (60xx is investigational and not approved.)

01/06/2026

Our mission is to revolutionize the drug discovery process by integrating biology, chemistry, and artificial intelligence, delivering novel therapeutics to patients with speed, precision, and purpose.